Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nevro Corp.
New 24-month data from the SENZA-PDN trial, presented at the American Diabetes Society conference in New Orleans, provides more support for HFX 10 kHz as a reliable therapy for people with painful diabetic neuropathy.
The Australian company secured $125m in financing to support commercialization of the Evoke SCS system for chronic pain beginning in late 2022. The US FDA approved Evoke SCS for chronic intractable pain of the trunk and/or limbs, the third major FDA approval of an SCS technology this year so far.
The FDA approved a diabetic peripheral neuropathy indication for Medtronic’s Intellis and Vanta spinal cord stimulators a few days after expanding the indication for Senza Nevro’s spinal cord stimulation system to include non-surgical refractory back pain.
UnitedHealthcare will provide coverage for Nevro’s HFX spinal cord stimulation therapy for the treatment of painful diabetic neuropathy beginning on 1 March. Analysts believe the decision bodes well for the company’s chances of securing coverage from other insurers.
- Implantable Devices
- Other Names / Subsidiaries
- Nevro Medical Limited
- Nevro Medical Pty Ltd.
- Nevro Medical Sarl